Hologic, Inc. filings document the company’s transition from a Nasdaq-listed public issuer to a private company after its completed acquisition by funds managed by Blackstone and TPG. The record includes Form 25 notice for removal of Hologic common stock from Nasdaq listing and Form 15 certification to terminate registration or suspend Exchange Act reporting duties for its common stock.
Related 8-K disclosures cover material events, merger-related agreements and shareholder voting matters, capital-structure disclosures, governance and compensation arrangements, operating results, and clinical or regulatory developments tied to Hologic’s women’s health medical-technology business.
Hologic Inc ownership filing shows Vanguard Capital Management beneficially owned 16,721,923 shares of common stock, representing 7.49% of the class as of 03/31/2026. The filing reports sole voting power over 2,218,009 shares and sole dispositive power over the full 16,721,923 shares. The disclosure states these holdings reflect securities managed across Vanguard affiliates and funds.
Hologic, Inc. executive Jan Verstreken reported changes to his equity awards in connection with the company’s closing merger with Hopper Parent Inc. At the merger’s effective time, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right worth up to $3.00 in cash, if payable. Outstanding stock options, restricted stock units and performance stock units held by Verstreken were cancelled or converted into cash- and CVR-based rights consistent with this merger consideration. As a result of the transaction, he no longer beneficially owns any shares of Hologic common stock.
Hologic Inc. reported that Brandon Schnittker, President, GYN Surgical, had his equity awards settled in connection with the company’s merger into a wholly owned subsidiary of Hopper Parent Inc. Each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right (CVR) for up to an additional $3.00 in cash.
Multiple non-qualified stock options, performance stock units and 17,644 shares of common stock were disposed of to the issuer, and performance stock units were certified and then converted into the cash-and-CVR merger consideration. As a result of the merger, Schnittker no longer beneficially owns any Hologic common stock, directly or indirectly.
Hologic Inc President, Diagnostic Solutions Jennifer M. Schneiders reported multiple equity award adjustments tied to the company’s merger. On April 7, 2026, she disposed of 41,462 shares of common stock back to the issuer and surrendered several non-qualified stock option grants covering 3,804, 4,058, 10,028 and 18,698 underlying shares.
Footnotes state that, under the October 21, 2025 merger agreement, each Hologic common share was converted into the right to receive $76.00 in cash plus a contingent value right of up to $3.00 in cash per share. Restricted stock units and performance stock units were converted into cash- and CVR-based rights and then cancelled. As a result of the merger, Schneiders no longer beneficially owns any Hologic common stock.
Hologic Inc.’s Chief Financial Officer Karleen Oberton reported the cash-out of her equity awards in connection with Hologic’s merger with Hopper Parent Inc. At the merger’s effective time, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right (CVR) representing up to an additional $3.00 in cash.
On the same date, Oberton disposed of multiple non‑qualified stock option grants covering tens of thousands of shares at exercise prices between $45.61 and $79.39, as well as performance stock units and 150,735 shares of common stock back to the issuer. A performance‑based award of 42,707 performance stock units was certified and then cancelled for the merger consideration. As a result of the merger, she no longer beneficially owns any Hologic common stock, with her equity position replaced by the cash and CVR rights defined in the merger agreement.
Hologic, Inc. Chief Operating Officer Mitchell D. Essex reported merger-related equity changes tied to the company’s acquisition. On April 7, 2026, his non‑qualified stock options covering 2,972, 11,596, 25,070 and 32,722 shares of common stock were disposed of back to the issuer, ending those option positions.
The filing also shows 46,154 performance stock units certified and then cancelled, and 77,694 shares of common stock disposed to the issuer at the merger’s effective time. Under the merger terms, each Hologic common share was converted into the right to receive $76.00 in cash plus a contingent value right for up to $3.00 in cash per share. As a result of these transactions, Essex no longer beneficially owns any Hologic common stock.
Hologic, Inc. completed a merger in which Hopper Merger Sub combined with the company, making Hologic a wholly owned subsidiary of Hopper Parent Inc. At the effective time, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right for up to an additional $3.00 in cash per share.
For General Counsel Anne M. Liddy, all outstanding stock options, performance stock units, restricted stock units, and 28,052 shares of common stock were disposed of to the issuer or converted into rights to receive the merger consideration. As a result of the merger, she no longer beneficially owns any Hologic common stock.